October 2021 in “Dermatology Reports” Tofacitinib, a hair regrowth treatment, may worsen acne.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
1 citations
,
May 2025 in “The Journal of Rheumatology” Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
February 2026 in “Annals of Case Reports” Tofacitinib helped a patient regrow hair after 40 years of total hair loss.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
3 citations
,
August 2025 in “Frontiers in Pharmacology” Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
10 citations
,
September 2021 in “The FASEB Journal” ACKR2 helps prevent skin scarring and hair loss by controlling inflammation.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
February 2026 in “Journal of Drugs in Dermatology” Janus kinase inhibitors are effective and safe for treating alopecia areata.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
July 2025 in “Russian Journal of Clinical Dermatology and Venereology” Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.
May 2026 in “Acta Dermato Venereologica” Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
9 citations
,
January 2024 in “International Journal of Dermatology” JAK inhibitors show promise in treating moderate to severe alopecia areata.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.